Introduction: To offer patients with EGFR mutationpositive advanced NSCLC appropriate EGFR tyrosine kinase inhibitor treatment, mutation testing of tumor samples is required. However, tissue/cytologic samples are not always available or evaluable. The large, noninterventional diagnostic ASSESS study (NCT01785888) evaluated the utility of
Methods: ASSESS was conducted in 56 centers (in Europe and Japan). Eligible patients (with newly diagnosed locally advanced/metastatic treatment-naive advanced NSCLC) provided diagnostic tissue/cytologic and plasma samples. DNA extracted from tissue/cytologic samples was subjected *Corresponding author.
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to EGFR mutation testing using local practices; designated laboratories performed DNA extraction/mutation testing of blood samples. The primary end point was level of concordance of EGFR mutation status between matched tissue/cytologic and plasma samples.
Results: Of 1311 patients enrolled, 1288 were eligible. Concordance of mutation status in 1162 matched samples was 89% (sensitivity 46%, specificity 97%, positive predictive value 78%, and negative predictive value 90%). A group of 25 patients with apparent false-positive plasma results was overrepresented for cytologic samples, use of less sensitive tissue testing methodologies, and smoking habits associated with high EGFR mutation frequency, indicative of falsenegative tumor results. In cases in which plasma and tumor samples were tested with identical highly sensitive methods, positive predictive value/sensitivity were generally improved.
Conclusions: These real-world data suggest that ctDNA is a feasible sample for EGFR mutation analysis. It is important to conduct mutation testing of both tumor and plasma samples in specialized laboratories, using robust/sensitive methods to ensure that patients receive appropriate treatments that target the molecular features of their disease.
Introduction
NSCLC accounts for approximately 83% of all lung cancers, and most patients present with advanced disease at diagnosis.
1 Adenocarcinoma (ADC), which is among the most common of the NSCLC histological subtypes, has been shown to be associated with activating mutations in the EGFR gene in 13% of European and 47% of Japanese patients (corresponding rates for non-ADC 5% and 7%, respectively). 2 Response to EGFR tyrosine kinase inhibitors (TKIs) is acknowledged to be greater in patients with tumors harboring activating mutations in the tyrosine kinase domain of the EGFR gene versus wild-type EGFR. Furthermore, EGFR TKIs have demonstrated efficacy superior to that of doublet chemotherapy in patients with EGFR mutation-positive advanced NSCLC. [4] [5] [6] [7] [8] Clinical guidelines 9, 10 and several working groups 11, 12 thus advocate mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC to confirm suitability for EGFR TKI treatment. However, tissue/cytologic samples are not always available or evaluable for diagnosis and mutation testing, leaving some patients unable to have the EGFR mutation status of their tumors determined. 13 Several studies have demonstrated that it is feasible to assess EGFR mutation status by using circulating free tumor-derived DNA (ctDNA), which can be isolated from the plasma or serum of patients with NSCLC. 4, 14 Indeed, nucleic acid released from tumor cells into the circulation represents an alternative source of tumor-derived DNA, an approach referred to as liquid biopsy. 13 Indicative of the clinical relevance of ctDNA in mutation analysis, the presence of EGFR mutations in ctDNA has been found to predict response to EGFR TKIs 7, 13, 15 ; similar objective response rates and progression-free survival have also been observed between patients with EGFR mutation-positive NSCLC detected by testing of tissue/cytologic samples and patients with EGFR mutations detected in their ctDNA. 4 Indeed, an amendment to the summary of product characteristics for the EGFR TKI gefitinib stating that ctDNA may be used for mutation analysis of NSCLC when tumor samples are unavailable 16 was adopted by the Committee for Medicinal Products for Human Use in September 2014.
As ctDNA analysis is technically challenging, it is important that the accuracy, suitability, and feasibility of use of ctDNA for mutation analysis in clinical practice be established. In the open-label IFUM study of white patients with EGFR mutation-positive NSCLC, between 652 evaluable matched tissue/cytologic and plasma (ctDNA) samples, mutation status concordance was 94%, demonstrating a high accuracy of ctDNA-based mutation testing with respect to tissue-based testing. 4 However, there is a need to confirm such findings outside of the controlled clinical trial environment to improve local diagnostic practice, enable wider access to ctDNA mutation testing, and provide more patients with the opportunity to receive therapies personalized to the mutation status of their tumors. The large, multicenter, noninterventional, diagnostic ASSESS study (NCT0178588) investigated the utility of ctDNA for EGFR mutation testing in a real-world diagnostic setting.
Materials and Methods

Study Design and Participants
Eligible patients were those at least 18 years of age (!20 years in Japan) with histologically/cytologically confirmed, systemic treatment-naive, locally advanced NSCLC (stage IIIA/B according to the American Joint Committee on Cancer staging system) unsuitable for curative treatment or chemoradiotherapy or with metastatic disease (stage IV) and those with recurrent disease after previous curative treatment (resection and/or adjuvant chemotherapy). Provision of a diagnostic tissue/cytologic sample and a fresh blood (plasma) sample at enrollment was mandatory. The blood sample was taken before initiation of any treatment.
The primary end point of ASSESS was the level of concordance between EGFR mutation status obtained by tissue/cytologic testing and that obtained by blood (plasma)-based testing. Secondary end points included EGFR mutation testing practices and mutation frequency and correlations between mutation status and demographic data/disease status and treatment decisions after mutation testing (not reported).
All patients provided written, informed consent. Study approval was obtained from the independent ethics committees at each institution. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization/Good Clinical Practice, applicable regulatory requirements for noninterventional studies, and AstraZeneca's policy on bioethics and human biological samples.
Procedures
EGFR mutation testing and results data for tumor samples obtained before enrollment in ASSESS were used where available (see Fig. 1A ). For tests conducted in ASSESS, diagnostic tissue/cytologic samples were subjected to EGFR mutation testing as per local practices after histopathological review (WHO classification 17 ) to ensure that samples were adequate for use. Each patient provided a 10-mL blood sample, which was processed to plasma, frozen, and transported to designated laboratories for mutation testing. In Europe, 43 academic, hospital, and commercial laboratories performed the tissue/cytologic testing and five central/regional expert laboratories were used for blood-based testing. In Japan, two commercial laboratories were used for both tissue/cytologic and blood-based testing.
Outcomes
Testing methodologies, sample types and availability, testing turnaround time, and testing success rate/ mutation detection rate were captured to assess EGFR mutation testing practices. Concordance of EGFR mutation status between matched tissue/cytologic and plasma samples was assessed by using the following: concordance rate; sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) (Supplementary Table 1 ); and exact two-sided 95% confidence interval (CI).
Statistical Analyses
Concordance of EGFR mutation status between matched tissue/cytologic and plasma samples was calculated for the evaluable population (all eligible patients with known tumor [tissue/cytologic] and plasma sample mutation status). The sample size of ASSESS was calculated to allow accurate determination of sensitivity between tumor-and blood-based testing. patients with EGFR mutation-positive NSCLC, if the sensitivity was 50%, the 95% CI would be expected to be 40% to 60%. Assuming a 10% prevalence of EGFR mutations in Europe, it was estimated that 1000 patients should be tested to obtain 100 with EGFR mutation-positive NSCLC. As an independent replication, sensitivity was obtained in patients from Japan; assuming a 30% prevalence of EGFR mutations in Japan, it was estimated that 300 patients should be tested to obtain 100 with EGFR mutation-positive NSCLC.
EGFR mutation testing practices (enrolled population) and EGFR mutation frequency (evaluable tumor/ plasma populations) were summarized by using appropriate descriptive statistics. 
Results
Patients
From April 11, 2013, to April 17, 2014, a total of 1311 patients were enrolled (Table 1) , 1288 of whom were eligible (Fig. 2) . A total of 23 patients were enrolled in error (they did not fulfil the inclusion/exclusion criteria) and were not included in the final analysis (Supplementary Table 2 ).
Sampling Methodologies and EGFR Mutation Testing Practices
Tissue/cytologic samples were mostly collected during current diagnosis (Supplementary Fig. 1A ) and most often sampled from the primary tumor ( Supplementary  Fig. 1B) . The most frequent sampling sites were the lungs/lymph nodes ( Supplementary Fig. 1C ). Bronchoscopy was the most frequently used sample collection method ( Supplementary Fig. 1D ). A range of mutation testing methods for tissue/cytologic samples (>10) were observed in Europe versus only two methods in Japan (Fig. 1A) . The mutation testing methods observed for plasma were limited and differed between Europe and Japan (Fig. 1B) .
The median EGFR test turnaround time for tissue/ cytologic samples was 11 days for Europe (95% CI: 14.0-17.3) and 8 days for Japan (95% CI: 8.2-14.1); mutation testing success rates were high in both Europe (98%) and Japan (<100%). Mutation tests were not performed on the tissue/cytologic samples of 110 patients and results were not obtained from the tested samples of 17 patients. The most frequent reason for not testing was insufficient material provided (60% [47 of 78 responses to the question] in Europe and 56% [five of nine] in Japan). There were no obvious differences in sampling methods between evaluable and nonevaluable tissue/cytologic samples.
EGFR Mutation Frequency
The overall EGFR mutation frequency was 16% for evaluable tissue/cytologic samples and 9% for evaluable plasma samples (Table 2) . Consistent with previous reports, 2 in Europe, 14% of ADC tissue/cytologic samples (99 of 712) and 3% of non-ADC samples (six of 180) were EGFR mutation-positive. In Japan, 40% of ADC tissue/cytologic samples (78 of 195) and 8% (six of 77) of non-ADC samples were EGFR mutation-positive.
Concordance of EGFR Mutation Status between Matched Tissue/Cytologic and Plasma Samples
Overall concordance of mutation status was 89% (sensitivity 46%, specificity 97%, PPV 78%, and NPV 90%) (Table 3 ). An EGFR mutation-positive result in plasma and mutation-negative result in tissue/cytologic testing were observed in samples from 25 patients (false-positive rate 22%); the demographics and sampling/mutation testing methodologies associated with these patients are summarized in Supplementary Table 3 ).
Furthermore, in a subset of 94 Japanese patients, sensitivity increased from an initial result of 17% (five of 29) to 52% (15 of 29) when samples that had originally had ctDNA extracted using the Qiagen QIAamp MinElute Virus Spin Kit for DNA (400 mL plasma) had extraction repeated using the Qiagen QIAamp Circulating Nucleic Acid Kit (3 mL plasma) specifically designed to isolate smaller, fragmented DNA, even though the same 
Discussion
To our knowledge, ASSESS is the most comprehensive study of real-world EGFR mutation testing practices in Europe and Japan. ASSESS was designed to evaluate how data obtained using local practices for tissue/cytologic and plasma sample testing compare with data obtained from well-controlled clinical testing that is generally performed in a single expert laboratory.
The mutation status concordance observed between 1162 matched tissue/cytologic and plasma samples (89%) suggests that ctDNA is a feasible sample for realworld EGFR mutation analysis if robust/sensitive DNA extraction and mutation analysis methodologies are used. ctDNA comprises less than 1% of total circulating free DNA 18 ; including data from the subset of patients who had DNA reextracted with an optimized method increased the overall concordance rate and sensitivity.
The low PPV (78%) raised a concern that some of the plasma EGFR mutation results might be false positives, and 25 patients for whom testing yielded apparent falsepositive plasma results were identified (Supplementary Table 3 ). This group was overrepresented for cytologic samples, which may not be representative of the disease, and/or the use of less sensitive DNA sequencing methodologies (56% of these 25 tumor samples were tested by DNA sequencing/pyrosequencing versus 25% of samples from the overall population [305 of 1201]). In addition, 80% of these patients were never-, former, or light smokers, a subgroup in which a higher EGFR mutation frequency is expected. Furthermore, in Europe, the EGFR mutation frequency by DNA sequencing/ pyrosequencing of tissue/cytologic samples was 10% (37 of 370) versus 15% (68 of 465) for all other methods combined, suggesting that DNA sequencing/ pyrosequencing may have missed some of the EGFR mutations present. This finding is in agreement with results of external quality assessment studies that have revealed a high rate of genotyping errors in Europe, where less sensitive techniques are still frequently used. 19, 20 Overall, these data suggest that the low PPV was due to false-negative results in tumor rather than to false-positive results in plasma. False-negative results can occur because of tumor heterogeneity, inexperience, or use of methods with low sensitivity.
In contrast, it is clear that a negative result in plasma may be incorrect (false-negative), as ctDNA mutation analysis may not pick up EGFR mutations in all patients who carry them in their tumors. The sensitivity of plasma tests, which is indicative of how likely they are to accurately detect EGFR mutations, varied (36%-100%) between countries. ASSESS revealed substantial differences within/between Europe and Japan in the mutation testing methodologies used, reflecting differences in available and/or accessible equipment and knowledge, which may contribute to this variation. However, overall sensitivity (46%) was markedly lower than the pooled sensitivities reported in two recent meta-analyses of concordance of EGFR mutation status between matched tissue/cytologic and plasma samples (62%-67%). 21, 22 Caution is advised when comparing data from clinical trials, in which testing is generally well controlled and performed in a single central laboratory, with the real-world ASSESS data. Of note, the concordance rate of 94% (sensitivity 66%, specificity 100%, PPV 99%, and NPV 94%) reported for IFUM was higher than in ASSESS. 4 Likewise, the sensitivity and PPV were higher in FASTACT-2 23 (75% and 94%, respectively) and sensitivity in the EURTAC study 24 This confirms the findings of the IFUM study, 4 which indicated that when an EGFR mutation is detected in ctDNA, the result can be trusted and a prescriber can conclude that the patient is likely to benefit from TKI therapy.
In real-world practice, test sensitivity may be further complicated by the different stage/differentiation of the disease, 25 which likely influence release of ctDNA into blood. In ASSESS, a higher frequency of EGFR mutations was observed in the plasma of patients with M1b disease (13%) versus M1a disease (7%) despite the EGFR mutation frequency in tumor being similar in these two groups, which is consistent with the hypothesis of greater release of ctDNA in patients with distant metastases. It must be noted that analysis of ctDNA may allow identification of mutations in heterogeneous tumors that could carry a specific variant in only a minor tumor clone (i.e., beyond the "biopsy zone"). However, although plasma-based testing requires standardization as a technique under relatively early investigation, the ASSESS results suggest that further improvements in mutation analysis of tissue/cytologic samples are still required to reduce the occurrence of false-negative results.
In IFUM, 19% of patients had nonevaluable tissue/ cytologic samples for reasons including low tumor content, insufficient sample quality/quantity, poor/ inappropriate fixation, and no DNA. 4 In this respect, accurate and accessible ctDNA mutation testing to address the unmet need in patients without an available/evaluable tumor sample will be important to enable more patients to receive therapies personalized to the mutation status of their tumor.
Conclusions
These ASSESS real-world data suggest that ctDNA is a feasible sample for EGFR mutation analysis when tumor samples are unavailable. It is important to conduct mutation testing of both tumor and plasma samples in specialized laboratories, using robust and sensitive mutation testing methods to ensure accuracy of results.
